FDA Organizational
Structure
A complete expert-level map of how FDA is organized — every product center, every key operating office, every division you'll interact with in a regulatory career. Knowing who does what inside FDA is the difference between filing with the right people and wasting months in the wrong queue.
Why Structure Matters in Practice
FDA is not a monolith. It is an agency of approximately 18,000 employees organized into product-specific centers, field offices, and cross-cutting programs. When you submit a food facility registration, it goes to CFSAN. When you file a 510(k) for a medical device, it goes to CDRH. When a shipment is detained at the Port of Los Angeles, it's ORA field staff making the call — not CFSAN, not CDER.
This matters for practical reasons. Filing a drug application with the wrong center causes delays, not automatic rejection — but those delays can cost months and hundreds of thousands of dollars. Calling the wrong FDA office for guidance wastes everyone's time. Understanding the structure lets you give clients precise, actionable guidance rather than vague regulatory advice.
Know the Building Before You Enter the Room
Every FDA regulatory engagement begins with the same question: which center governs this product? That question determines the forms, the fees, the timelines, the contact points, and the review criteria. Getting this wrong at the start cascades into every subsequent step.
FDA's Top-Level Structure
At the top, FDA is led by the Commissioner of Food and Drugs, a presidential appointee confirmed by the Senate. The Commissioner oversees the entire agency including all product centers, field operations, and policy offices.
Below the Commissioner are two parallel organizational tracks that a consultant interacts with:
Understanding that centers make policy and ORA enforces it is one of the most useful structural insights in FDA regulatory affairs. When a facility gets a warning letter, the investigation is typically led by ORA field staff, but the letter itself is issued by the relevant product center.
CFSAN — Center for Food Safety & Applied Nutrition
- Human food and beverages (all categories except meat/poultry)
- Dietary supplements (vitamins, minerals, herbs, botanicals)
- Infant formula — most heavily regulated food category
- Bottled water (in addition to EPA for tap water)
- Cosmetics — now mandatory registration under MoCRA
- Food additives and color additives (approval petitions)
- Food packaging and food contact materials
- Seafood, juice, and retail food HACCP programs
- Food Facility Registration (Form FDA 3537) — FURLS system
- FSMA — Preventive Controls, FSVP, Produce Safety Rule
- GRAS (Generally Recognized as Safe) notifications
- Food additive petitions (21 CFR Part 171)
- Color additive petitions
- MoCRA — Cosmetics Direct system for facility registration
- New Dietary Ingredient (NDI) notifications
- Infant formula notifications and recalls
- Office of Nutrition and Food Labeling (ONFL) — Sets food labeling requirements; reviews health claims; manages Nutrition Facts panel regulations. This is the office whose rules govern most of what a food label must say.
- Office of Food Additive Safety (OFAS) — Reviews food additive petitions and GRAS notifications. If your client's product uses a novel ingredient, OFAS is who determines if it's legal.
- Office of Cosmetics and Colors (OCC) — Implements MoCRA; manages cosmetic facility registration and product listing; reviews color additive petitions.
- Office of Dietary Supplement Programs (ODSP) — Reviews NDI notifications; monitors supplement GMP compliance; coordinates with ORA on supplement inspections.
CDER — Center for Drug Evaluation & Research
- Human prescription drugs (brand name and generic)
- Over-the-counter (OTC) drugs and OTC monographs
- Generic drugs (ANDA pathway)
- Certain therapeutic biologics (transferred from CBER in 2003)
- Drug manufacturing facilities (domestic and foreign)
- Drug advertising and promotion (through OPDP)
- Drug labeling — prescribing information, package inserts
- NDA — New Drug Application (21 CFR Part 314)
- ANDA — Abbreviated New Drug Application (generics)
- IND — Investigational New Drug Application
- Drug Establishment Registration (DRLS/SPL system)
- Drug Listing via Structured Product Labeling (SPL)
- OTC Monograph system (now administrative order process)
- PDUFA — user fee program funding review timelines
CDER is organized around therapeutic review divisions — each responsible for a specific disease area. When you submit an NDA, it goes to the division that handles that therapeutic category. Knowing which division reviews your drug can affect strategy, timing, and communication approach.
- Office of New Drugs (OND) — The largest office; contains all therapeutic review divisions. Oversees NDA and BLA (for CDER biologics) reviews.
- Office of Generic Drugs (OGD) — Reviews all ANDA submissions. Has its own review staff and timeline commitments under GDUFA.
- Office of Pharmaceutical Quality (OPQ) — Reviews chemistry, manufacturing, and controls (CMC) sections of drug applications. Coordinates with ORA on cGMP inspections.
- Office of Prescription Drug Promotion (OPDP) — Reviews and regulates prescription drug advertising and promotional materials. Issues untitled letters and warning letters for misleading drug promotion.
- Office of Surveillance and Epidemiology (OSE) — Post-market drug safety surveillance; receives and analyzes adverse event reports from MedWatch.
- Office of Regulatory Policy (ORP) — Handles drug labeling policy, citizen petitions, and regulatory exclusivity questions.
CDRH — Center for Devices & Radiological Health
- Medical devices (Class I, II, and III — all risk levels)
- Radiation-emitting electronic products (X-ray, laser, microwave)
- In vitro diagnostic (IVD) devices — lab tests, home tests
- Software as a Medical Device (SaMD) — AI/ML-based devices
- Combination products (device + drug, device + biologic)
- Personal protective equipment (some categories)
- 510(k) — Premarket Notification (most common device pathway)
- PMA — Premarket Approval (Class III, highest risk)
- De Novo — Novel low-to-moderate risk devices without predicate
- Q-Submission (Pre-Sub) — Pre-submission meeting program
- UDI — Unique Device Identification system
- GUDID — Global UDI Database
- Device Establishment Registration and Device Listing (FURLS)
- Office of Product Evaluation and Quality (OPEQ) — The primary review office for 510(k), PMA, and De Novo submissions. Organized into review divisions by device specialty (cardiovascular, orthopedic, diagnostic, etc.).
- Office of Strategic Partnerships and Technology Innovation (OSPTI) — Handles the Pre-Submission (Q-Sub) program; coordinates with sponsors before formal submission. This is where smart device companies engage FDA early to de-risk their submissions.
- Office of Regulatory Programs (ORP) — Manages device establishment registration, device listing, and the UDI program.
- Office of Surveillance and Biometrics (OSB) — Manages the Medical Device Reporting (MDR) system for adverse events; oversees post-market surveillance studies.
CVM — Center for Veterinary Medicine
- Veterinary prescription and OTC drugs
- Medicated animal feeds
- Animal food and pet food (all species)
- Veterinary devices (some; shared with CDRH)
- Aquaculture products and drugs
- Veterinary biologics (shared with USDA APHIS)
- Food safety for animal-derived human food (residues)
- NADA — New Animal Drug Application
- ANADA — Abbreviated New Animal Drug Application (generics)
- Conditional Approval — Minor use/minor species pathway
- INAD — Investigational New Animal Drug
- Animal food facility registration (FURLS — same as human food)
- Veterinary drug establishment registration
- Veterinary drug GMP (21 CFR Parts 226/229)
This distinction trips up many international clients — and even some consultants. The rule is the same as for human products: intended use determines the category.
- Pet food claiming "supports joint health" → Animal food/supplement → Regulated under CFSAN/CVM food framework → Registration required, GMP required, but no NADA needed
- Same product claiming "treats arthritis" → Veterinary drug → Requires an approved NADA or ANADA before U.S. marketing — no exceptions
- Withdrawal periods → Veterinary drugs used in food-producing animals (cattle, poultry, fish) must specify how long after the last dose the animal's meat, milk, or eggs are safe for human consumption. Missing this on a label is a serious violation.
CBER — Center for Biologics Evaluation & Research
- Vaccines (all human vaccines for infectious disease)
- Blood and blood components (whole blood, plasma, platelets)
- Cellular therapies (CAR-T, stem cell products)
- Gene therapy products
- Tissue and cellular products (HCT/Ps)
- Allergenics (allergy immunotherapy products)
- Devices used with biological products
- BLA — Biologics License Application (21 CFR Part 601)
- Biosimilar BLA (351(k) pathway)
- IND for biologic studies
- Lot release — mandatory pre-distribution testing for vaccines and some blood products
- Blood establishment registration
- HCT/P donor eligibility and good tissue practice (GTP)
CBER has a unique requirement that does not exist for other FDA-regulated products: lot release. For certain products — primarily vaccines, blood products, and some allergenics — every manufactured lot must be tested and released by CBER before it can be distributed. This means FDA actively tests the product, not just reviews the manufacturer's data. It is the most intensive pre-distribution oversight FDA conducts for any product category.
ORA — The Office of Regulatory Affairs
ORA is FDA's field force — the operational arm that turns policy into enforcement. While the product centers develop regulations and review submissions from their offices in the Washington D.C. area, ORA staff are in the field: inspecting factories in China, examining shipments in Los Angeles, collecting samples in Miami, and serving warning letters in New Jersey.
- Conducts facility inspections (domestic and foreign) across all product categories
- Screens imports at 300+ ports of entry using PREDICT risk system
- Collects product samples for laboratory analysis
- Issues Notice of Inspection (Form FDA 482)
- Presents Inspectional Observations (Form FDA 483)
- Recommends enforcement actions to product centers
- Coordinates with CBP on import admissibility decisions
- 5 Regional Offices: Northeast, Mid-Atlantic, Southeast, Central, Pacific
- 20 District Offices: Each covers a multi-state area; has dedicated investigators, compliance officers, and import operations staff
- Division of Import Operations (DIOP): Specifically manages the Prior Notice system, import alerts, and admissibility decisions for food imports
- International Posts: ORA has staff stationed in China, India, Europe, Latin America, and the Middle East for foreign facility inspections
When ORA interacts with a facility, you'll encounter two types of staff:
- FDA Investigator (Consumer Safety Officer / Investigator) — Conducts the physical inspection, collects samples, presents the Form 483 at closeout. An investigator's job is to observe and document — not to make enforcement decisions. Investigators are thorough, often technical, and follow detailed inspection protocols called "assignments" issued by the relevant product center.
- Compliance Officer — Reviews the Establishment Inspection Report (EIR) written by the investigator. The compliance officer makes the recommendation: NAI, VAI, or OAI. If OAI, the compliance officer drafts the warning letter and recommends enforcement action. Compliance officers are the decision-makers — investigators are the fact-finders.
Other Key Offices Every Consultant Should Know
Beyond the five product centers and ORA, FDA has several cross-cutting offices whose work directly affects consultants and their clients.
| Office | Abbreviation | Primary Function | When You'll Encounter It |
|---|---|---|---|
| Office of the Commissioner | OC | Policy leadership; issues FDA-wide guidances and positions; media relations | Major policy changes; FDA Safety Communications; pandemic responses |
| Office of Regulatory Policy | ORP | Rulemaking coordination; citizen petitions; regulatory exclusivity determinations | When filing a citizen petition; when challenging a competitor's exclusivity claim |
| Office of Criminal Investigations | OCI | Criminal investigations of fraudulent submissions, tampering, counterfeit products | Serious fraud cases; counterfeit drug investigations; clinical trial fraud |
| Office of Minority Health and Health Equity | OMHHE | Ensures regulated products serve diverse populations; diversity in clinical trials | Clinical trial design; health equity considerations in drug labeling |
| Office of External Affairs | OEA | Congressional affairs; stakeholder engagement; public meetings | Industry meetings; public comment periods on proposed rules |
| Office of Scientific Investigations | OSI (under ORA) | Inspects clinical trial sites for GCP compliance; reviews clinical data integrity | During NDA/BLA review when FDA audits the clinical trials supporting the application |
How the Centers Interact — And Why It Matters
The product centers operate largely independently, but there are important points of interaction — particularly for products that fall between categories, or products that combine elements from multiple categories.
Combination Products — The Intercenter Agreement
A combination product is a product that combines a drug, device, and/or biologic into a single entity. Examples include drug-eluting stents (device + drug), autoinjectors (device + drug), and gene therapy vectors (biologic + device). For combination products, FDA must determine which center has "primary jurisdiction" — and that determination significantly affects the regulatory pathway, requirements, and fees.
The Office of Combination Products (OCP), within the Office of the Commissioner, makes this determination through a formal Request for Designation (RFD) process. If you have a client with a combination product, filing an RFD early is essential — it takes 60 days and determines everything downstream.
The Smart Insulin Pen
A South Korean medical technology company develops an insulin pen that both delivers insulin (a drug) and has a connected Bluetooth sensor that tracks doses and sends data to a smartphone app (a device with SaMD elements). They ask you: "Which center do we file with?"
The answer requires an RFD. Based on the primary mode of action — insulin delivery is the primary therapeutic function — OCP would likely designate this as a drug-led combination product with CDER as lead center, with CDRH involved for the device components. This means:
- The insulin component needs an NDA (or piggybacks on existing insulin approval)
- The device component needs to meet applicable device requirements
- Labeling must satisfy both drug and device labeling requirements
- Manufacturing must comply with both drug cGMP and device QSR
FDA Guidances — How Policy Gets Communicated
Between formal regulations (which are binding law published in the CFR) and informal enforcement decisions, FDA communicates its current thinking through guidance documents. Guidances are not legally binding — companies can take alternative approaches if they can demonstrate equivalence — but in practice, following FDA guidance is almost always the path of least resistance.
Every center issues guidances specific to its product area. Understanding how to find, read, and apply guidances is a core regulatory consulting skill.
Pro Tip — Subscribe to FDA's Guidance Notification System: FDA emails notifications when new or revised guidances are published. Subscribe at fda.gov/about-fda/contact-fda/subscribe-podcasts-and-news-feeds. Organized by center and product category, these notifications let you know immediately when a guidance affecting your clients is issued — before most of your competition has noticed.
The Docket System — How the Public Interacts with FDA
FDA uses a public docket system to manage formal public input on proposed rules, guidance documents, and petitions. The docket system is managed at regulations.gov. Every proposed rule and draft guidance has a docket number, and anyone — including international companies and their consultants — can submit comments.
Understanding the docket system is valuable for three reasons:
- Monitoring regulatory changes: You can track proposed rules affecting your clients' product categories in real time, before they become final
- Filing citizen petitions: Companies can petition FDA to take (or refrain from taking) specific regulatory actions — citizen petitions are filed through the docket system
- Commenting on guidance: During comment periods, you can submit technical comments that influence how a guidance is finalized — a form of regulatory advocacy available to any party
Mapping FDA Structure to Your Consulting Practice
Here is a practical mapping of the most common client situations to the FDA organizational unit you'll engage with:
| Client Situation | Primary FDA Unit | What You'll Need to Navigate |
|---|---|---|
| Foreign food exporter — first shipment to U.S. | CFSAN / ORA (DIOP) | Food facility registration (FURLS), US Agent designation, Prior Notice system, FEI number |
| Cosmetic brand — post-MoCRA compliance | CFSAN (OCC) | Cosmetics Direct registration, product listing, safety substantiation records, INCI ingredient declarations |
| Foreign generic drug manufacturer | CDER (OGD) / ORA | Drug establishment registration, annual facility fee (~$75K), SPL drug listing, ANDA submission, pre-approval inspection |
| Medical device company — Class II product | CDRH (OPEQ) | Device establishment registration, device listing, 510(k) submission, UDI/GUDID, QSR compliance |
| Veterinary drug manufacturer | CVM | Drug establishment registration, NADA or ANADA, veterinary drug labeling review, GMP compliance |
| Dietary supplement brand | CFSAN (ODSP) | Food facility registration (supplements are food), NDI notification if needed, GMP (21 CFR Part 111), claims review |
| Shipment detained at U.S. port | ORA (district office) / DIOP | Notice of detention response, voluntary submission of evidence, working with customs broker, potential refusal |
| Warning letter received | ORA + relevant product center | Written response to the Center Director, per-issue corrective action plan, documented corrections with evidence |
| Combination product (device + drug) | OCP → CDER or CDRH | Request for Designation (RFD), intercenter agreement, dual compliance requirements |
The Probiotic That Got Lost Between Centers
A Thai company produces a probiotic product. They want to export to the U.S. Their existing marketing says: "Contains 10 billion live cultures. Clinically proven to reduce symptoms of Irritable Bowel Syndrome (IBS)."
Their U.S. distributor's compliance team asks you to help them register the facility. You read the label and immediately recognize the problem: "clinically proven to reduce symptoms of IBS" is a disease claim. IBS is a specific diagnosed medical condition. This claim transforms the product from a dietary supplement (CFSAN) into an unapproved drug (CDER).
This product cannot legally enter the U.S. in its current form. Your options for the client:
- Option A: Remove the IBS claim; replace with "supports digestive health" (structure/function claim) → back to CFSAN → facility registration + supplement GMP
- Option B: Pursue an NDA with CDER as a drug for IBS → multi-year, multi-million dollar pathway → probably not viable for this client
- FDA has 5 product centers (CFSAN, CDER, CDRH, CVM, CBER) plus the Office of Regulatory Affairs (ORA) for field operations. Centers make policy; ORA enforces it.
- CFSAN governs food, dietary supplements, and cosmetics — the center most relevant for the majority of international exporters. Registration is free; FSMA compliance is where the complexity lies.
- CDER governs human drugs. Foreign drug establishment fees are approximately $75,000/year — a figure that requires early client communication. Drug listing via SPL is technically complex.
- CDRH governs medical devices. The Q-Submission (Pre-Sub) program — free, takes 75 days — is dramatically underused and can save device clients months of delay and wasted submission fees.
- CVM governs veterinary drugs and animal food. The food-vs-drug distinction applies equally to animal products: a disease claim on pet food makes it an animal drug requiring NADA approval.
- CBER governs biologics. It is the most specialized center. Know enough to identify CBER-regulated products and refer clients to biologics specialists rather than attempting work beyond your expertise.
- ORA investigates and recommends enforcement; compliance officers make the OAI/VAI/NAI determination. Understanding this distinction improves 483 response strategy significantly.
- Combination products go through the Office of Combination Products (OCP) for a Request for Designation — always file this early to avoid filing in the wrong center.